Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00004853
Other study ID # 000092
Secondary ID 00-C-0092
Status Completed
Phase Phase 1
First received
Last updated
Start date March 3, 2000
Est. completion date May 20, 2009

Study information

Verified date January 27, 2016
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Filgrastim (granulocyte colony-stimulating factor), which is administered by daily subcutaneous injection after cytotoxic chemotherapy, shortens the duration of chemotherapy-induced neutropenia and lowers the risk of infection. In children treated with dose-intensive chemotherapy, filgrastim reduces the duration of severe neutropenia and, as a result, has become a standard component of the treatment regimen. Filgrastim-SD/01 (AMGEN), which is produced by PEGylation of the amino-terminus of filgrastim, is a sustained duration form of granulocyte colony-stimulating factor. In phase I and phase II trials in adults, a single dose of Filgrastim-SD/01 appears to be equivalent to daily dosing of filgrastim in enhancing neutrophil recovery and has a comparable adverse event profile.

Dose-intensive vincristine/cyclophosphamide/doxorubicin (VDoxC) alternating with ifosfamide/etoposide (IE) has become standard therapy for children and adolescents with Ewing's sarcoma and other sarcomas treated at the POB/NCI and other cancer centers within the US. Supportive care measures used in children who are treated with this regimen include mesna to prevent oxazaphosphorine urotoxicity, dexrazoxane to reduce doxorubicin cardiotoxicity, and filgrastim to shorten the duration of neutropenia. The purpose of this randomized open label trial is to compare the tolerance, toxicity, and therapeutic effects of Filgrastim-SD/01 given as a single injection after chemotherapy to daily subcutaneous filgrastim in patients with newly diagnosed sarcoma. The pharmacokinetics of Filgrastim-SD/01 will also be compared to the pharmacokinetics of filgrastim. This trial will also be a platform for performing biological studies of these tumors and for detailed cardiac studies. High-risk patients who are treated on this front line trial and respond will also be candidates for a planned transplant protocol. A total of 34 patients (17 patients per treatment arm) will be entered onto the trial.


Description:

Background:

- Filgrastim (granulocyte colony-stimulating factor), which is administered by daily subcutaneous injection after cytotoxic chemotherapy, shortens the duration of chemotherapy-induced neutropenia and lowers the risk of infection.

- In children treated with dose-intensive chemotherapy, Filgrastim reduces the duration of severe neutropenia and, as a result, has become a standard component of the treatment regimen.

- Filgrastim-SD/01 (AMGEN), which is produced by PEGylation of the amino-terminus of Filgrastim, is a sustained duration form of granulocyte colony-stimulating factor.

- In phase I and phase II trials in adults, a single dose of Filgrastim-SD/01 appears to be equivalent to daily dosing of Filgrastim in enhancing neutrophil recovery and has a comparable adverse event profile.

- Dose-intensive vincristine/cyclophosphamide/doxorubicin (VDoxC) alternating with ifosfamide/etoposide (IE) has become standard therapy for children and adolescents with Ewing's sarcoma and other sarcomas treated at the POB/NCI and other cancer centers within the US.

Objectives:

- Compare the tolerance, toxicity, and therapeutic effects of Filgrastim-SD/01 given as a single injection after chemotherapy to daily subcutaneous Filgrastim in patients with newly diagnosed sarcoma receiving multi-agent, dose intensive chemotherapy.

- The pharmacokinetics of Filgrastim-SD/01 will also be compared to the pharmacokinetics of Filgrastim.

- This trial will also be a platform for performing biological studies of these tumors study neutrophil function and CD34 mobilization, and for detailed cardiac studies.

Eligibility:

- Children and young adults (less than or equal to 25 years) with previously untreated high-risk sarcomas (Ewing sarcoma, rhabdomyosarcoma, MPNST, and synovial sarcoma).

- No evidence of tumor infiltration of the bone marrow.

Design:

- Participants will be randomized (1:1) to receive a single dose of Filgrastim-SD/01 or daily filgrastim as a SQ injection after each cycle of chemotherapy.

- Standard 5 drug dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide will be administered.

- Surgery or radiation for the primary tumor will occur after cycle 5.

- A total of 34 patients (17 patients per treatment arm) will be entered onto the trial.


Other known NCT identifiers
  • NCT00020137

Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date May 20, 2009
Est. primary completion date May 20, 2009
Accepts healthy volunteers No
Gender All
Age group N/A to 25 Years
Eligibility - INCLUSION CRITERIA:

- Newly diagnosed histologically proven:

- Ewing's sarcoma family of tumors, including peripheral neuroectodermal tumors;

- Alveolar rhabdomyosarcoma;

- Stage 3 or 4 embryonal rhabdomyosarcoma;

- Malignant peripheral nerve sheath tumor that is unresectable, incompletely resected with bulk residual disease or metastatic;

- Synovial cell sarcoma that is unresectable, incompletely resected with bulk residual disease, or metastatic.

- Age equal to or less than 25 years at the time of diagnosis.

- Normal cardiac function (ejection fraction by MUGA or ECHO that is within the institutional normal range).

- Normal serum creatinine for age or creatinine clearance greater than 60 ml/min/1.73m(2).

- Normal liver function (SGPT less than 5 times the upper limit of normal and bilirubin less than 2.5 times the upper limit of normal).

- Normal hematologic function (absolute neutrophil count equal to or greater than 1500/microL, hemoglobin equal to or greater than 9.0 g/dl and platelet count equal to or greater than 100,000/microL).

- Subjects of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

EXCLUSION CRITERIA:

- Previous chemotherapy or radiotherapy.

- Pregnant or breast feeding females because the chemotherapy administered on this trial could have a detrimental effect on the developing fetus or newborn.

- Histological evidence of tumor infiltration of bone marrow.

- Stage 1 or 2 embryonal rhabdomyosarcomas.

Study Design


Intervention

Biological:
Filgrastim
5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
Filgrastim-SD/01
100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)

Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304. Review. — View Citation

Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood. 1989 Sep;74(4):1303-7. — View Citation

Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996 Sep 15;88(6):1907-29. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Tolerance and toxicity 1 year
Primary PKs 1 year
Secondary Compare neutrophil function
Secondary Compare CD34 positive stem cell mobilization
Secondary Compare days of febrile neutropenia, days on antibiotics, and inpatient days resulting from neutropenia
Secondary Evaluate the role of functional cardiac MRI and serum troponin T levels in detecting early doxorubicin cardiotoxicity
Secondary Assess methods of detecting minimal residual disease
Secondary cDNA microarray analysis of gene expression, development of cell lines and xenotransplantation models, and exploration of apoptotic pathways
See also
  Status Clinical Trial Phase
Recruiting NCT04388839 - Evolutionary Therapy for Rhabdomyosarcoma Phase 2
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT00520936 - A Study of Pemetrexed in Children With Recurrent Cancer Phase 2
Completed NCT03655587 - Impact of an Orthotic Intervention in Children With Peripheral Neuropathy N/A
Recruiting NCT06094101 - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Phase 1/Phase 2
Recruiting NCT04625907 - FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma Phase 1/Phase 2
Active, not recruiting NCT04095221 - A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Phase 1/Phase 2
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Recruiting NCT04337177 - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Phase 1
Active, not recruiting NCT02945800 - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Phase 2
Not yet recruiting NCT06029465 - Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT00592592 - Proton RT for the Treatment of Pediatric Rhabdomyosarcoma Phase 2
Completed NCT00187174 - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors Phase 1
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT05093322 - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Phase 1/Phase 2
Completed NCT04956198 - Drug Sensitivity and Mutation Profiling
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2